The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis
Open accessAbstract
Background: Treatment-resistant schizophrenia (TRS) is associated with high levels of functional impairment, healthcare usage and societal costs. Cross-sectional studies may overestimate TRS rates because of selection bias. Aims: We aimed to quantify TRS rates by using first-episode cohorts to improve resource allocation and clozapine access. Method: We undertook a systematic review of TRS rates among people with first-episode psychosis and schizophrenia, with a minimum follow-up of 8 weeks. We searched PubMed, PsycINFO, EMBASE, CINAHL and the Cochrane Database of Systematic Reviews, and meta-analysed TRS rates from included studies. Results: Twelve studies were included, totalling 11 958 participants; six studies were of high quality. The rate of TRS was 22.8% (95% CI 19.1–27.0%, P < 0.001) among all first-episode cohorts and 24.4% (95% CI 19.5–30.0%, P < 0.001) among first-episode schizophrenia cohorts. Subgroup sensitivity analyses by location of recruitment, TRS definition, study quality, time of data collection and retrospective versus prospective data collection did not lead to statistically significant differences in heterogeneity. In a meta-regression, duration of follow-up and percentage drop-out did not significantly affect the overall TRS rate. Men were 1.57 times more likely to develop TRS than women (95% CI 1.11–2.21, P = 0.010). Conclusions: Almost a quarter of people with first-episode psychosis or schizophrenia will develop TRS in the early stages of treatment. When including people with schizophrenia who relapse despite initial response and continuous treatment, rates of TRS may be as high as a third. These high rates of TRS highlight the need for improved access to clozapine and psychosocial supports.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Self-citationSex Differences in the Risk of Schizophrenia: Evidence From Meta-analysis
Aleman, A., Kahn, R. S., & Selten, J.-P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.565 · Cited by 818
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Self-citationTime Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia
Lieberman, J. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170047006 · Cited by 442
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
International trends in clozapine use: a study in 17 countries
Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K., Garuoliené, K., Hoffmann, F., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12742 · Cited by 314 · cited 2×
“Given low levels of clozapine prescribing in some jurisdictions, 9 quantifying the rates of patients with TRS could highlight the need to improve access to clozapine, 13 and increase opportunities of a clozapine trial for patients with TRS. Cross-sectional studies examining the proportion of…”
Lally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., Mondelli, V., Reis Marques, T., Pariante, C., Dazzan, P., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291716002014 · Cited by 298
Self-citationAntipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
Demjaha, A., Lappin, J. M., Stahl, D., Patel, M. X., MacCabe, J. H., Howes, O. D., Heslin, M., Reininghaus, U. A., Donoghue, K., Lomas, B., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000435 · Cited by 289
Self-citationVermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246
Agid, O., Arenovich, T., Sajeev, G., Zipursky, R. B., Kapur, S., Foussias, G., & Remington, G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05785yel · Cited by 224
Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study
MALLA, A., NORMAN, R., SCHMITZ, N., MANCHANDA, R., BÉCHARD-EVANS, L., TAKHAR, J., & HARICHARAN, R. (2006) · Psychological Medicine · doi:10.1017/s0033291706007379 · Cited by 217
Kahn, R. S., Winter van Rossum, I., Leucht, S., McGuire, P., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30252-9 · Cited by 193
The clinical course of schizophrenia in women and men—a nation-wide cohort study
Sommer, I. E., Tiihonen, J., van Mourik, A., Tanskanen, A., & Taipale, H. (2020) · npj Schizophrenia · doi:10.1038/s41537-020-0102-z · Cited by 178
Iasevoli, F., Giordano, S., Balletta, R., Latte, G., Formato, M. V., Prinzivalli, E., De Berardis, D., Tomasetti, C., & de Bartolomeis, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.08.010 · Cited by 176
Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study
Wimberley, T., Støvring, H., Sørensen, H. J., Horsdal, H. T., MacCabe, J. H., & Gasse, C. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00575-1 · Cited by 153
Self-citationPrescriber and institutional barriers and facilitators of clozapine use: A systematic review
Verdoux, H., Quilès, C., Bachmann, C., & Siskind, D. J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.046 · Cited by 146
Self-citationThe impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Self-citationJohnson, S., Sathyaseelan, M., Charles, H. S., Jeyaseelan, V., & Jacob, K. S. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-159 · Cited by 93
Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
Rubio, J. M., Taipale, H., Correll, C. U., Tanskanen, A., Kane, J. M., & Tiihonen, J. (2020) · Psychological Medicine · doi:10.1017/s0033291719001296 · Cited by 45
Emsley, R., Asmal, L., Rubio, J. M., Correll, C. U., & Kane, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.025 · Cited by 41
Clozapine Use in a Cohort of First-Episode Psychosis
Doyle, R., Behan, C. L., O’Keeffe, D., Masterson, S., Kinsella, A., Kelly, A., Sheridan, A., Keating, D., Hynes, C., Madigan, K. V., et al. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000734 · Cited by 34
Siskind, D. J., Harris, M., Pirkis, J., & Whiteford, H. (2011) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796011000734 · Cited by 32
Self-citationSiskind, D. J., Harris, M., Phillipou, A., Morgan, V. A., Waterreus, A. J., Galletly, C. A., Carr, V. J., Harvey, C. A., & Castle, D. J. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000305 · Cited by 31
Self-citationSiskind, D. J., Harris, M., Pirkis, J., & Whiteford, H. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-012-0590-x · Cited by 28
Self-citationPsychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?
Rubio, J. M., & Kane, J. M. (2017) · Schizophrenia · doi:10.1038/s41537-017-0039-z · Cited by 16
Todorović, A., Lal, S., Dark, F. L., Monte, V. E. D., Kisely, S. R., & Siskind, D. J. (2020) · Journal of Mental Health · doi:10.1080/09638237.2020.1836558 · Cited by 16
Self-citationÜçok, A., Çıkrıkçılı, U., Ergül, C., Tabak, Ö., Salaj, A., Karabulut, S., & Correll, C. U. (2016) · CNS Drugs · doi:10.1007/s40263-016-0358-z · Cited by 15
Yoshimura, B., Sakamoto, S., Sato, K., Takaki, M., & Yamada, N. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12531 · Cited by 9
Cited by
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Metadata
- Authors
- Siskind, D., Orr, S., Sinha, S., Yu, O., Brijball, B., Warren, N., MacCabe, J. H., Smart, S. E., & Kisely, S.
- Venue
- The British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2021-05-11
- Volume
- 220
- Issue
- 3
- Pages
- 115-120
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W3161940807
- Cited by
- 255
- References
- 38
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.